Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/ea8191indicate #pcsm #ProstateCancer Aware cc: @nehavapiwala

#ICYMI - .Alex Shoushtari, MD Memorial Sloan Kettering Cancer Center leads Alliance for Clinical Trials in Oncology A091903, a phase II trial to test whether nivolumab in combination with cabozantinib works in patients with mucosal #melanoma . To learn more, visit bit.ly/Alliance-A0919… #NCI #NCTN #CancerResearch Melanoma Research Foundation

May is #SkinCancerAwarenessMonth , Check out #NCICTEP #NCTN #skincancer #melanoma trials portfolio. All trials are active. Learn more: buff.ly/2QZ1EXd

Create Access to Targeted Cancer Therapy for -Underserved Populations (CATCH-UP.2020), were awards to eight National Cancer Institute cancer centers, to rapidly accrue patients from underserved populations to #ETCTN precision medicine trials. #NationalMinorityHealthMonth . buff.ly/3b4BoSY

#DYK : .Thomas Hope UC San Francisco .Sukhmani (Suki) Padda MD Cedars-Sinai are leading a trial (@ALLIANCE_org A021901) that studies the effect of everolimus vesus 177Lu-dotatate in patients with bronchial #neuroendocrine tumors? Learn more: bit.ly/Alliance-A0219… #bronchialcancer #NCI #NCTN .ECOG-ACRIN Cancer Research Group

#ETCTN (10577) is a new #clinicaltrial for patients with #solidtumors that have spread from where they first started (primary), to nearby tissue, lymph nodes, or distant parts of the body (advanced), or other places in the body (metastatic). ➡️ Learn more: buff.ly/4cWWgce

Newly Activated #NCTN #BrainCancer #Glioblastoma Trial: (EAF223) Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial ( #GABLE ), led by ECOG-ACRIN Cancer Research Group Learn more: buff.ly/3JpebuQ

Newly Activated #NCTN #Myeloma Trial: (A062102) Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients, led by Dr. Tuchman Sascha Tuchman UNC Lineberger Alliance for Clinical Trials in Oncology Learn more: buff.ly/4d0v0cM

Thanks to all for an inspiring #AACR24 #CancerResearch meeting. The #NCICTEP team looks forward to seeing everyone again soon in “Chi-town” for #AACR25 ! #Gratitude

#Sarcomas are rare types of #cancer that begin in bone or in the soft tissues of the body. See this #AACR24 abstract for results from #ETCTN phase 2 #clinicaltrial , of #atezolizumab (atezo), in patients (pts) with advanced #sarcoma cancers . (NCI 10398). buff.ly/3xthFK5

Join us tomorrow (April 9, 2024 at 3:35 PM - 3:45 PM PT) for an update on #ETCTN (10217) #clinicaltrial , which assessed the combo of Copa (pan-PI3K inhibitor) and Ola (PARP inhibitor) in #solidtumors harboring mutations in PI3K/AKT or DDR pathways. #AACR24 buff.ly/4alinY5

‼️ Coming to #AACR24 THIS Tuesday, April 9. Check it out ➡️ #ETCTN #clinicaltrial (9455) update…an open-label, two-part, phase II, single-arm, multicenter study for patients with triple-negative breast cancer ( #TNBC ). Vishnu Prasath, MD, MS #cancerresearch buff.ly/3VTWLxw

Check out different cohort results from the following #AACR24 poster presentations, based on #NCICTEP SWOG Cancer Research Network #clinicaltrial S1609 (DART), AACR annual meeting on April 9, 2024, 1:30 PM - 5:00 PM. More: buff.ly/3UdwFER

Join #AACR24 #NCICTEP Dr. Smith’s presentation 'Molecular characterization initiative (MCI): Update and feedback on expanding to other cancers', at 2:35 PM - 2:45 PM on April 9, 2024. More: buff.ly/3J4Fb2n

Check it out 👉 #AACR24 poster “An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program”, on April 7, 2024, 1:30 PM - 5:00 PM. More: buff.ly/3VFu1Zu

The 2024 AACR annual meeting starts in a few days (April 5 - 10)! Stay tuned for #NCICTEP #cancerresearch abstracts and presentations coming out hot! #AACR24 meeting website: aacr.org/meeting/aacr-a…

#ETCTN (10605) is a new #clinicaltrial for patients with #colorectalcancer that has not responded to previous treatment (refractory) and that has spread from where it first started to other places in the body (metastatic). buff.ly/49dJpiP #ColorectalCancerAwarenessMonth

#ETCTN (10466) is still accepting new patients.

Dr. Ramaprasad Srinivasan of the NCI Urologic Oncology Branch, leads this important study for patients diagnosed with hereditary #leiomyomatosis and #renalcellcancer ( #HLRCC ).

See more at: buff.ly/4cx72FV. #KidneyCancerAwarenessMonth